BTLA anticorps (Extracellular)

N° du produit ABIN7877534

Cet anticorps Souris Monoclonal détecte spécifiquement BTLA dans ELISA. Il présente une réactivité avec des échantillons de Humain.

Aperçu rapide pour BTLA anticorps (Extracellular) (ABIN7877534)

Antigène: BTLA (B and T Lymphocyte Associated (BTLA))

Reactivité: Humain

Hôte: Souris

Clonalité: Monoclonal

Conjugué: Cet anticorp BTLA est non-conjugé

Application: ELISA

Classe de qualité: Carrier-free

Clone: BTLA-1528

Détail du produit anti-BTLA anticorps

Épitope: Extracellular

Fonction: BTLA Antibody / CD272 (azide and preservative free)

Purification: Protein G affinity chromatography

Immunogène: Recombinant extracellular human CD272/BTLA protein was used as the immunogen for this BTLA antibody.

Isotype: IgG2b, kappa

Information d'application

Indications d'application: Optimal dilution of the BTLA antibody should be determined by the researcher.

Restrictions: For Research Use only

Stockage

Format: Liquid

Concentration: 1 mg/mL

Buffer: 1 mg/mL in 1X PBS, BSA free, sodium azide free

Agent conservateur: Azide free

Stock: 4 °C,-20 °C

Stockage commentaire: Store the BTLA antibody at 2-8oC (with azide) or aliquot and store at -20oC or colder (without azide).

Détails sur BTLA

Antigène: BTLA (B and T Lymphocyte Associated (BTLA))

Autre désignation: BTLA

Sujet: B and T lymphocyte attenuator (BTLA) is an immunoglobulin domain-containing glycoprotein whose expression is induced during T-cell activation. BTLA is similar to CTLA-4 and PD-1, all of which are coinhibitory receptors belonging to the CD28 family. However, unlike CTLA-4 and PD-1, BTLA does not interact with B7-Ig family counter receptors. Rather, the herpesvirus entry mediator (HVEM), a TNF receptor, acts as a molecular switch that modulates T-cell activation by propagating inhibitory signals through BTLA. The BTLAHVEM interaction is conserved between Mouse and human, suggesting that this system is an important pathway regulating lymphocyte activation.

UniProt: Q7Z6A9

Pathways: Cancer Immune Checkpoints